Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Roth Capital Maintains Buy On Pharmacyclics Following Waldenstrom’s EMA Submission Acceptance http://www.smarteranalyst.com/2014/12/01/roth-capital-maintains-buy-on-pharmacyclics-following-waldenstroms-ema-submission-acceptance/
Roth Capital Reiterates Buy On Regeneron Following Priority Review Acceptance http://www.smarteranalyst.com/2014/12/01/roth-capital-reiterates-buy-on-regeneron-following-priority-review-acceptance/
$FSC MLV Maintains Hold On Fifth Street Finance Following Fiscal 4Q14 Results http://www.smarteranalyst.com/2014/12/01/mlv-maintains-hold-on-fifth-street-finance-following-fiscal-4q14-results/
$TGTX Roth Capital Maintains Buy On TG Therapeutics Following Initiation Of Phase I/Ib Combination Study http://www.smarteranalyst.com/2014/12/01/roth-capital-maintains-buy-on-tg-therapeutics-following-initiation-of-phase-iib-combination-study/
Roth Capital Maintains Buy On TG Therapeutics Following Initiation Of Phase I/Ib Combination Study http://www.smarteranalyst.com/2014/12/01/roth-capital-maintains-buy-on-tg-therapeutics-following-initiation-of-phase-iib-combination-study/
$IMUC Maxim Maintains Buy On ImmunoCellular Following Positive Regulatory Feedback From EMA http://www.smarteranalyst.com/2014/12/01/maxim-maintains-buy-on-immunocellular-following-positive-regulatory-feedback-from-ema/
$IMUC Maxim Maintains Buy On ImmunoCellular Following Positive Regulatory Feedback From EMA http://www.smarteranalyst.com/2014/12/01/maxim-maintains-buy-on-immunocellular-following-positive-regulatory-feedback-from-ema/
$ISR Maxim Reiterates Buy On IsoRay Following Barrow Study Results; Keeps $5 PT http://www.smarteranalyst.com/2014/12/01/maxim-reiterates-buy-on-isoray-following-barrow-study-results-keeps-5-pt/
$ISR Maxim Reiterates Buy On IsoRay Following Barrow Study Results; Keeps $5 PT http://www.smarteranalyst.com/2014/12/01/maxim-reiterates-buy-on-isoray-following-barrow-study-results-keeps-5-pt/
$AEZS Maxim Group Reiterates Buy On Aeterna Zentaris Following Collaboration Agreement With Sinopharm A-Think http://www.smarteranalyst.com/2014/12/01/maxim-group-reiterates-buy-on-aeterna-zentaris-following-collaboration-agreement-with-sinopharm-a-think/
$AEZS Maxim Group Reiterates Buy On Aeterna Zentaris Following Collaboration Agreement With Sinopharm A-Think http://www.smarteranalyst.com/2014/12/01/maxim-group-reiterates-buy-on-aeterna-zentaris-following-collaboration-agreement-with-sinopharm-a-think/
$GPRO GoPro: Rumored Drone Not A High-Flyer, Says Oppenheimer http://www.smarteranalyst.com/2014/12/01/gopro-rumored-drone-not-a-high-flyer-says-oppenheimer/
$GPRO GoPro: Rumored Drone Not A High-Flyer, Says Oppenheimer http://www.smarteranalyst.com/2014/12/01/gopro-rumored-drone-not-a-high-flyer-says-oppenheimer/
$INVN Roth Capital Maintains Buy On InvenSense, Sees 73% Upside For The Stock http://www.smarteranalyst.com/2014/12/01/roth-capital-maintains-buy-on-invensense-sees-73-upside-for-the-stock/
$SRPT Roth Capital Reiterates Buy On Sarepta Therapeutics, Sees 31% Upside http://www.smarteranalyst.com/2014/12/01/roth-capital-reiterates-buy-on-sarepta-therapeutics-sees-31-upside/
$SRPT Roth Capital Reiterates Buy On Sarepta Therapeutics, Sees 31% Upside http://www.smarteranalyst.com/2014/12/01/roth-capital-reiterates-buy-on-sarepta-therapeutics-sees-31-upside/
$VRTX Vertex: If Royalty Rights Sold for $3.3B, How Much Is the CF Franchise Worth? Maxim's Jason Kolbert Answers http://www.smarteranalyst.com/2014/12/01/vertex-if-royalty-rights-sold-for-3-3b-how-much-is-the-cf-franchise-worth-maxims-jason-kolbert-answers/
$DVAX MLV Reiterates Buy On Dynavax Technologies As It Regains Rights To DV1179 http://www.smarteranalyst.com/2014/12/01/mlv-reiterates-buy-on-dynavax-technologies-as-it-regains-rights-to-dv1179/
$AVNR Cowen Remains Positive On Avanir Pharmaceuticals Following FDA CRL For AVP-825 http://www.smarteranalyst.com/2014/12/01/cowen-reiterates-remains-positive-on-avanir-pharmaceuticals-following/
$AVNR Cowen Remains Positive On Avanir Pharmaceuticals Following FDA CRL For AVP-825 http://www.smarteranalyst.com/2014/12/01/cowen-reiterates-remains-positive-on-avanir-pharmaceuticals-following/
$ILMN Wedbush Comments On Illumina Following 'Poorly Diligenced GenomeWeb Article' Release http://www.smarteranalyst.com/2014/11/28/wedbush-comments-on-illumina-following-poorly-diligenced-genomeweb-article-release/
$KERX Maxim Raises Keryx Biopharmaceuticals Price Target As KOLs Give Strong Endorsement To Auryxia http://www.smarteranalyst.com/2014/11/28/maxim-raises-keryx-biopharmaceuticals-price-target-as-kols-give-strong-endorsement-to-auryxia/
$KERX Maxim Raises Keryx Biopharmaceuticals Price Target As KOLs Give Strong Endorsement To Auryxia http://www.smarteranalyst.com/2014/11/28/maxim-raises-keryx-biopharmaceuticals-price-target-as-kols-give-strong-endorsement-to-auryxia/
$YGE Roth Capital Remains On The Sidelines About Yingli Green Energy Following 3Q14 Results
$VEEV William Blair Keeps Bullish Stance On Veeva Systems Following Earnings http://www.smarteranalyst.com/2014/11/28/william-blair-keeps-bullish-stance-on-veeva-systems-following-earnings/
$VEEV William Blair Keeps Bullish Stance On Veeva Systems Following Earnings http://www.smarteranalyst.com/2014/11/28/william-blair-keeps-bullish-stance-on-veeva-systems-following-earnings/
$SDRL Morgan Stanley Remains Positive On Seadrill Following Meeting With Chairman http://www.smarteranalyst.com/2014/10/14/morgan-stanley-remains-positive-on-seadrill-following-meeting-with-chairman/
$SDRL Morgan Stanley Remains Positive On Seadrill Following Meeting With Chairman http://www.smarteranalyst.com/2014/10/14/morgan-stanley-remains-positive-on-seadrill-following-meeting-with-chairman/
Alibaba And The 16 Tiger Cubs http://www.smarteranalyst.com/contributor/2014/11/27/alibaba-and-the-16-tiger-cubs/
$HLF If Herbalife’s Recent Press Release Seems Too Good to Be True, It’s Because It Is http://www.smarteranalyst.com/contributor/2014/11/27/if-herbalifes-recent-press-release-seems-too-good-to-be-true-its-because-it-is/
If Herbalife’s Recent Press Release Seems Too Good to Be True, It’s Because It Is http://www.smarteranalyst.com/contributor/2014/11/27/if-herbalifes-recent-press-release-seems-too-good-to-be-true-its-because-it-is/
$HPQ BMO Maintains Market Perform On Hewlett-Packard After Q4 Earnings; Chooses To Sit On The Sidelines http://www.smarteranalyst.com/2014/11/26/bmo-maintains-market-perform-on-hewlett-packard-after-q4-earnings-chooses-to-sit-on-the-sidelines/
$HPQ BMO Maintains Market Perform On Hewlett-Packard After Q4 Earnings; Chooses To Sit On The Sidelines http://www.smarteranalyst.com/2014/11/26/bmo-maintains-market-perform-on-hewlett-packard-after-q4-earnings-chooses-to-sit-on-the-sidelines/
$BDSI William Blair Reiterates Outperform On Biodelivery Sciences Following Management Meetings With investors http://www.smarteranalyst.com/2014/11/26/william-blair-reiterates-outperform-on-biodelivery-sciences-following-management-meetings-with-investors/
$DE Deere: The Near-Term Negative Catalysts Are Played, But Downside Remains, Says William Blair http://www.smarteranalyst.com/2014/11/26/deere-the-near-term-negative-catalysts-are-played-but-downside-remains-says-william-blair/
$EXAS William Blair Reiterates Outperform On Exact Sciences Following Issuance Of Final CMS Reimbursement Decision http://www.smarteranalyst.com/2014/11/26/william-blair-reiterates-outperform-on-exact-sciences-following-issuance-of-final-cms-reimbursement-decision/
$DANG Oppenheimer Cuts Dangdang Price Target Following 3Q14 Results, But Remains Positive http://www.smarteranalyst.com/2014/11/26/oppenheimer-cuts-dangdang-price-target-following-3q14-results-but-remains-positive/
$DANG Oppenheimer Cuts Dangdang Price Target Following 3Q14 Results, But Remains Positive http://www.smarteranalyst.com/2014/11/26/oppenheimer-cuts-dangdang-price-target-following-3q14-results-but-remains-positive/
$NUAN Wedbush Remains Neutral On Nuance Communications Following F4Q Results http://www.smarteranalyst.com/2014/11/26/wedbush-remains-neutral-on-nuance-communications-following-f4q-results/
$PANW William Blair Reiterates Outperform On Palo Alto Networks Following Earnings Results http://www.smarteranalyst.com/2014/11/26/william-blair-reiterates-outperform-on-palo-alto-networks-following-earnings-results/